Diagnostics
To inquire about our available technologies, call our office (813) 745-6828
| Name & Description | Number |
|---|---|
| Liquid Biopsy: Saliva Based Liquid Biopsy Assay for Oropharyngeal Cancer | 23MA001N |
| Liquid Biopsy: Non-Invasive Biospecimen Collection System | 23MB035N |
| Immunotherapy: Using 12 Chemokine Signature to Select Sting Agonist and TIL Treatments for Solid Tumors | 23MB031N |
| Method: Methods For Identifying Disseminated Cancer Cells In Breast Cancer Patients | 22MB118N |
| Method: Methods Of Treating Cancer Comprising Administration of Intratumoral DCs in combination with Systemic IgG Monoclonal Antibody | 22MB116N |
| Diagnostic: Secreted Rn Therapeutics for Nuclear Delivery | 22MB092N |
| Method: Altering Epigenetic Landscapes Control Progression and Refractory Disease States in Multiple Myeloma | 22MB090N |
| Detection: Novel Use of cdDNA to Identify Locally Advanced and Metastatic Upper Tract Urothelial Carcinoma | 22MA067N |
| Detection: Utilization Of Immortalized B Cells to Identify Sdcbp as a Novel Therapeutic Target in Ovarian Carcinoma | 22MA032N |
| Method: Systems And Methods for Predicting Hematological Conditions Using Methylation Data | 22MA017N |
| Method: Use Of Delta-Tocotrienol to Reduce the Progression of a Neoplasm to A Cancer | 22MA006N |
| Method: Compositions And Methods to Detect and Inhibit Nuclear Invasion of Cytoplasm or Mitochondria | 21MB095N |
| Prediction: Radiomics-Based Prediction of Severe Immune-Related Adverse Events in Patients with Lung Cancer | 21MB086N |
| Imaging: Systems And Methods for Derivation of Patent-Specific Tumor Dynamics Using a Spectral Analysis of An Image | 21MB081N |
| Prediction: Predictive Biomarker in Avastin in Later Stage Colon Cancer | 21MB066N |
| Immunotherapy: Quantifying The Tumor-Immune Ecosystem in Non-Small Cell Lung Cancer (NSCLC) To Identify Clinical Biomarkers of Therapy Response | 21MA044N |
| Detection: Circulating Tumor DNA and Methods of Use Thereof | 21MA036N |
| Prediction: Diagnostic To Support Clinical Trial Matching and Exploratory Biomarker Analyses in Cancer Patients | 21MA035N |
| Immunotherapy: Methods For Inhibiting Resistance to Immune Blockade Inhibitor Therapy | 21MA014N |
| Liquid Biopsy: Liquid Biopsy Based PCR Assay to Predict Drug Resistant in Prostate Cancer | 21MB071 |
| Liquid Biopsy: Liquid Biopsy Assay for Pan-cancer Early Detection Using Cell-free DNA Methylation | 21MB048 |
| Detection: Methods And Kits for the Detection of Malignancies | 20MA022N |
| Protein Diagnostic: Diagnostic to detect Leptomeningeal Disease | 20MB040N |
| Molecular Imaging Agent: A Novel Fluorescence Molecular Imaging Agent for Intraoperative Margin Assessment in Breast Cancer | 20MA008N |
| Diagnostic for Predicting Response to Therapies in Multiple Myeloma | 19MB057 13MB048 - VIDEO |
| Detection: Modeling Variability in Radiosensitivity and Tumor Immune Contexture to Personalize Radiotherapy | 19MB054N |
| Companion Diagnostic to Predict Response to Immunotherapy Based on the Methylation Status | 19MB052T2 |
| Methylation Status Diagnostic: Diagnostic to Predict Response to Immunotherapy | 19MB052 - VIDEO |
| Genetic Signature: Gene Signature to Distinguish between Metastatic Urothelial Carcinoma and Squamous Cell Carcinoma (Primary Lung and Metastatic Head & Neck) | 17MB044 |
| Genetic Biomarker: PTEN Loss of Expression as a Biomarker Response to GGTI-2418 Treatment | 17MA025 |
| Molecular Imaging: Predicting Response to Adjuvant Ipilimumab Treatment in Melanoma Using a Novel Algorithm to Analyze Nitric Oxide Levels in Peripheral Blood Immune Cells | 17MA002N |
| miRNA Diagnostic: miRNA Signature for Non-invasive Early Detection of Malignancy in IPMN | 17MA001 |